Bioinformatics Prediction of Potential Inhibitors For the SARS-CoV-2 NTPase/Helicase Using Molecular Docking and Dynamics Simulation From Organic Phenolic Compounds

massoud saidijam; Negin  Khaksarimehr; Mostafa Rezaei-Tavirani; Amir Taherkhani

doi:10.22037/jcma.v6i3.34490

Journal of Cellular & Molecular Anesthesia

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement New Publisher Announcement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v6i3.34490

Bioinformatics Prediction of Potential Inhibitors For the SARS-CoV-2 NTPase/Helicase Using Molecular Docking and Dynamics Simulation From Organic Phenolic Compounds

Author(s):

massoud saidijam^1,*,

Negin Khaksarimehr²,

Mostafa Rezaei-Tavirani

³,

Amir Taherkhani⁴

1Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

2School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.

3Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Journal of Cellular & Molecular Anesthesia:Vol. 6, issue 3; e150255

Published online:May 17, 2021

Article type:Original Articles

How to Cite:massoud saidijamNegin KhaksarimehrMostafa Rezaei-TaviraniAmir TaherkhaniBioinformatics Prediction of Potential Inhibitors For the SARS-CoV-2 NTPase/Helicase Using Molecular Docking and Dynamics Simulation From Organic Phenolic Compounds.J Cell Mol Anesth.6(3):e150255.https://doi.org/10.22037/jcma.v6i3.34490.

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a disorder with human-to-human rapid transmission. Besides several vaccines that have been represented, it is crucial to discover effective drugs to combat this infection in a short-period therapeutic procedure. The NTPase/helicase contributes to playing an important role in the replication of the viral RNA. Materials and methods: We estimated the binding affinity of several natural polyphenolics, commonly found in fruits and vegetables, with the catalytic site of SARS-CoV-2 helicase by molecular docking analysis using the AutoDock tool. The stability of connections between top-ranked components inside the catalytic site of the helicase was evaluated by molecular dynamics (MD) simulations. The most active residues within the catalytic site of the helicase were ranked based on their degree in a phenolics-residue interaction (PRI) network. Results: Amentoflavone, theaflavin 3'-gallate, and procyanidin were estimated to be the most potential effective SARS-CoV-2 helicase inhibitors with the salient inhibition constant value (Ki) at the picomolar scale. The energy of binding of these compounds with the helicase catalytic site was estimated between -13.90 and -12.77 kcal/mol. Asp534 and Leu412 demonstrated more degrees than the other residues. Conclusion: The present study predicts that amentoflavone, theaflavin 3'-gallate, and procyanidin might be helpful for the treatment of COVID-19.

Keywords

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

massoud saidijam:[PubMed][Scholar]
Negin Khaksarimehr:[PubMed][Scholar]
Mostafa Rezaei-Tavirani:[PubMed][Scholar]
Amir Taherkhani:[PubMed][Scholar]